11) Pharmaceutical Based Agents (PBAs)
Abstract
Focuses on therapeutic and proactive strategies to effectively minimize injuries and/or death resulting from exposure to PBAs. This will allow the Warfighter to maintain operational capacity in a chemically contested battlefield scenario. This effort involves the evaluation FDA approved therapeutics for operational use, as well as generation of novel drug products to enhance level of protection and/or operational utility for the Warfighter. Efforts in this area are designed to develop drug candidates that will ultimately be submitted for FDA licensure or to identify previously licensed products for new uses in the treatment and pretreatment against chemical warfare injury.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2023
- Source ID
- 9abb0388e1c9358e9490f05e252a0001